Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
: Personalized medicine in the treatment of acromegaly . European Journal of Endocrinology 2018 178 R89 – R100 . ( https://doi.org/10.1530/EJE-17-1006 ) 64 Cuevas-Ramos D Fleseriu M Pasireotide: a novel treatment for patients with acromegaly . Drug
Search for other papers by Xiuzhen Hou in
Google Scholar
PubMed
Search for other papers by Junfeng Zhang in
Google Scholar
PubMed
Search for other papers by Hehong Ma in
Google Scholar
PubMed
Search for other papers by Ming Li in
Google Scholar
PubMed
Search for other papers by Pei Wang in
Google Scholar
PubMed
, investigation and development of effective treatments against GDM are of essential clinical value. In order to sustain the fasting energy requirements during pregnancy, the endogenous production of glucose is increased by ~30% in pregnant women at the late
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
and treatment of acromegaly and to discuss novel and potential biomarkers of GH action in children and adults. Methods The structure of this Workshop was adapted from prior Workshops organized by GRS ( 6 , 7 , 8 ). Thirty-four invited
Search for other papers by Tatsuya Kondo in
Google Scholar
PubMed
Search for other papers by Nobukazu Miyakawa in
Google Scholar
PubMed
Search for other papers by Sayaka Kitano in
Google Scholar
PubMed
Search for other papers by Takuro Watanabe in
Google Scholar
PubMed
Search for other papers by Rieko Goto in
Google Scholar
PubMed
Search for other papers by Mary Ann Suico in
Google Scholar
PubMed
Search for other papers by Miki Sato in
Google Scholar
PubMed
Search for other papers by Yuki Takaki in
Google Scholar
PubMed
Search for other papers by Masaji Sakaguchi in
Google Scholar
PubMed
Search for other papers by Motoyuki Igata in
Google Scholar
PubMed
Search for other papers by Junji Kawashima in
Google Scholar
PubMed
Search for other papers by Hiroyuki Motoshima in
Google Scholar
PubMed
Search for other papers by Takeshi Matsumura in
Google Scholar
PubMed
Search for other papers by Hirofumi Kai in
Google Scholar
PubMed
Search for other papers by Eiichi Araki in
Google Scholar
PubMed
novel treatment strategy for NAFLD as well as metabolic disorders, including metabolic syndrome and type 2 diabetes. Supplementary materials This is linked to the online version of the paper at https://doi.org/10.1530/EC-21
Search for other papers by Yusaku Mori in
Google Scholar
PubMed
Maebashi Hirosegawa Clinic, Maebashi, Gunma, Japan
Search for other papers by Hiroyuki Shimizu in
Google Scholar
PubMed
Search for other papers by Hideki Kushima in
Google Scholar
PubMed
Search for other papers by Tomomi Saito in
Google Scholar
PubMed
Search for other papers by Munenori Hiromura in
Google Scholar
PubMed
Search for other papers by Michishige Terasaki in
Google Scholar
PubMed
Search for other papers by Masakazu Koshibu in
Google Scholar
PubMed
Search for other papers by Hirokazu Ohtaki in
Google Scholar
PubMed
Search for other papers by Tsutomu Hirano in
Google Scholar
PubMed
Introduction Nesfatin-1 is a novel peptide hormone that suppresses appetite through its actions in the central nervous system ( 1 , 2 ). Additionally, nesfatin-1 is directly involved in the regulation of the cardiovascular system ( 2 , 3
Search for other papers by E T Aristizabal Prada in
Google Scholar
PubMed
Search for other papers by C J Auernhammer in
Google Scholar
PubMed
often been limited by increased toxicity and side effects. Promising novel molecular targeting approaches to become translated into clinical treatment of NETs of the GEP system in the future might include strategies to target the CDK4/6-Rb-E2F axis or
Search for other papers by Peng Fan in
Google Scholar
PubMed
Search for other papers by Chao-Xia Lu in
Google Scholar
PubMed
Search for other papers by Di Zhang in
Google Scholar
PubMed
Search for other papers by Kun-Qi Yang in
Google Scholar
PubMed
Search for other papers by Pei-Pei Lu in
Google Scholar
PubMed
Search for other papers by Ying Zhang in
Google Scholar
PubMed
Search for other papers by Xu Meng in
Google Scholar
PubMed
Search for other papers by Su-Fang Hao in
Google Scholar
PubMed
Search for other papers by Fang Luo in
Google Scholar
PubMed
Search for other papers by Ya-Xin Liu in
Google Scholar
PubMed
Search for other papers by Hui-Min Zhang in
Google Scholar
PubMed
Search for other papers by Lei Song in
Google Scholar
PubMed
Search for other papers by Jun Cai in
Google Scholar
PubMed
Search for other papers by Xue Zhang in
Google Scholar
PubMed
Search for other papers by Xian-Liang Zhou in
Google Scholar
PubMed
PA was corrected by genetic analysis. A novel SCNN1B frameshift mutation was identified, confirming the diagnosis of LS. Screening of four generations of the family members and the use of tailored medicine for LS patients provide better management
Search for other papers by Eleftherios E Deiktakis in
Google Scholar
PubMed
Search for other papers by Eleftheria Ieronymaki in
Google Scholar
PubMed
Search for other papers by Peter Zarén in
Google Scholar
PubMed
Search for other papers by Agnes Hagsund in
Google Scholar
PubMed
Search for other papers by Elin Wirestrand in
Google Scholar
PubMed
Search for other papers by Johan Malm in
Google Scholar
PubMed
Search for other papers by Christos Tsatsanis in
Google Scholar
PubMed
Imperial College London, Institute of Reproductive and Developmental Biology, London, UK
Search for other papers by Ilpo T Huhtaniemi in
Google Scholar
PubMed
Malmö University Hospital, Reproductive Medicine Center, Malmö, Sweden
Search for other papers by Aleksander Giwercman in
Google Scholar
PubMed
Search for other papers by Yvonne Lundberg Giwercman in
Google Scholar
PubMed
Introduction For decades, gonadotropin-releasing hormone (GnRH) agonists have formed the mainstay hormonal treatment of prostate cancer ( 1 ). While they generate suppression of testosterone due to persistent suppression of luteinizing hormone
Search for other papers by Henrik H Thomsen in
Google Scholar
PubMed
Search for other papers by Holger J Møller in
Google Scholar
PubMed
Search for other papers by Christian Trolle in
Google Scholar
PubMed
Search for other papers by Kristian A Groth in
Google Scholar
PubMed
Search for other papers by Anne Skakkebæk in
Google Scholar
PubMed
Search for other papers by Anders Bojesen in
Google Scholar
PubMed
Search for other papers by Christian Høst in
Google Scholar
PubMed
Medical Research Laboratories, Departments of Clinical Biochemistry, Molecular Medicine, Department of Clinical Genetics, Department of Endocrinology and Internal Medicine, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
and KS is not fully understood and it is not known if the changes are entirely due to hypogonadism and most patients will require treatment with sex hormones for long periods of their lives. The low-grade inflammation seen in KS and TS are influenced
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Garvan Institute of Medical Research, New South Wales, Australia
School of Medical Sciences, University of New South Wales, New South Wales, Australia
Search for other papers by Vita Birzniece in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Department of Diabetes and Endocrinology, Westmead Hospital, New South Wales, Australia
Search for other papers by Teresa Lam in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Search for other papers by Mark McLean in
Google Scholar
PubMed
Search for other papers by Navneeta Reddy in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Search for other papers by Haleh Shahidipour in
Google Scholar
PubMed
Faculty of Medicine, Health and Human Sciences, Macquarie University, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia
Search for other papers by Amy Hayden in
Google Scholar
PubMed
Search for other papers by Howard Gurney in
Google Scholar
PubMed
Search for other papers by Glenn Stone in
Google Scholar
PubMed
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Steno Diabetes Center Odense, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Rikke Hjortebjerg in
Google Scholar
PubMed
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
controls ( 3 ). Insulin resistance is increased by more than 30% as early as 3 months after the initiation of ADT ( 4 ), and the risk of new-onset diabetes is increased four- to five-fold in the first year of treatment ( 5 ). These conditions are known to